White light colonoscopy is widely used to detect colorectal polyps, but flat and depressed lesions are often missed. Here, we report a molecular imaging strategy to potentially improve diagnostic performance by developing a fluorescently-labeled peptide specific for cMet. This 7mer is conjugated to Cy5.5, a near-infrared (NIR) cyanine dye. Specific binding to cMet was confirmed by cell staining, knockdown, and competition assays. The probe showed high binding affinity (k d = 57 nM) and fast onset (k = 1.6 min) to support topical administration in vivo. A mouse model (CPC;Apc) that develops spontaneous adenomas that overexpress cMet was used to demonstrate feasibility for real time in vivo imaging. This targeting ligand showed significantly higher target-to-background (T/B) ratio for polypoid and non-polypoid lesions by comparison with a scrambled control peptide. Immunofluorescence staining on human colon specimens show significantly greater binding to tubular and sessile serrated adenomas versus hyperplastic polyps and normal mucosa. These results demonstrate a peptide specific for cMet that is promising for endoscopic detection of pre-malignant lesions and guiding of tissue biopsy.
Results
Peptide specific for cMet. Phage display was used to biopan a linear heptapeptide library against the extra-cellular domain (ECD) of cMet. QQTNWSL showed the lowest P-value for binding interactions using a structural model for cMet. The C-terminus of this peptide was covalently linked with a Cy5.5 fluorophore via a GGGSK linker, hereafter QQT*-Cy5.5, Fig. 1A . The linker separates the peptide from the fluorophore to prevent steric hindrance. This sequence was scrambled as TLQWNQS for control, and was also labeled with Cy5.5, hereafter TLQ*-Cy5.5, Fig. 1B . 3D models show differences in biochemical structures, Fig. 1C ,D. Peak absorbance and emission occur in the near-infrared (NIR) spectrum, Fig. 1E ,F, where hemoglobin absorption, tissue scattering, and tissue autofluorescence are minimal. The peptides were synthesized with >95% purity by HPLC, and an experimental mass-to-charge ratio (m/z) of 1827.10 was measured using mass spectrometry, which agrees with expected values, Fig. S1A ,B. siRNA knockdown experiments were performed using human HT29 CRC cells to validate specific binding of QQT*-Cy5.5 to cMet. QQT*-Cy5.5 and anti-cMet-AF488 antibody showed strong binding to the surface of HT29 cells transfected with siCL (control) using confocal microscopy, Fig. 2A,B , while TLQ*-Cy5.5 displayed minimal binding, Fig. 2C . Fluorescence intensities were reduced with HT29 knockdown cells transfected with sicMet, Fig. 2D ,E. TLQ*-Cy5.5 revealed little signal, Fig. 2F . Quantified results showed this decrease to be significant, Fig. 2G . Western blot demonstrated effective knockdown of cMet expression, Fig. 2H . Significantly greater fluorescence intensity was observed for binding of QQT*-Cy5.5 and anti-cMet-AF488 to HT29 cells (cMet+) compared with human SW480 CRC cells (cMet−) cells, Fig. S2 . Similar results were found for mouse S114 (cMet+) and NIH3T3 (cMet−) cells, Fig. S3 . peptide characterization. Specific binding of QQT*-Cy5.5 to cMet was further supported by addition of unlabeled QQT* to compete for binding to HT29 cells. Fluorescence intensities decreased significantly with increasing concentrations of unlabeled QQT* but not with TLQ*, Fig. 3A . These results suggest that the peptide rather than either the linker or fluorophore mediates the binding interaction. By comparison, fluorescence intensities from binding of QQT*-Cy5.5 to HT29 cells did not change with addition of hepatocyte growth factor (HGF), a known ligand for cMet, at concentrations ranging from 0 to 100 ng/mL, Fig. S4A . A pull-down assay showed a strong band from QQT* binding to mouse cMet-ECD by comparison with that for TLQ*, Fig shows little binding. (G) A significant reduction is seen in intensity for QQT*-Cy5.5 and anti-cMet-AF488 for siCL versus sicMet transfected cells (2.9 and 4.1-fold change). TLQ*-Cy5.5 shows a non-significant decrease. The intensity for QQT*-Cy5.5 is significantly greater than that for TLQ*-Cy5.5 (8.1 fold-change). ANOVA models are fit with terms for 6 conditions to log-transformed data. 6 replicate slides are used for each condition with duplicate measures from each slide. The siCL versus sicMet difference for QQT*-Cy5.5 is significantly larger than the same difference for TLQ*-Cy5.5, P = 1.4 × Effect of peptide on cell signaling. No competition was observed between QQT* and HGF to support lack of interactions and effect on downstream signaling, Fig. S4A . These results suggest that the peptide and HGF bind to different sites on the cMet target. Western blots were performed to evaluate markers for activation of downstream cell signaling, Fig. 4A . Incubation of HGF (positive control) with HT29 cells showed strong phosphorylation activity for cMet (p-cMet), downstream AKT (p-AKT), and ERK1/2 (p-ERK1/2). By comparison, addition of QQT*-Cy5.5 at concentrations of 5 and 100 μM resulted in no change in phosphorylation of any substrate. An alamar blue assay showed no effect on growth of HT29 and CCD841 cells with addition of QQT*-Cy5.5 at concentrations of either 5 or 100 μM for 48 hours by comparison with HGF, Fig. 4B ,C. CCD841 normal colon cells was used to evaluate the effect of the peptide on the cell phenotype in non-tumor cells.
Validation of binding with cells in vitro.
In vivo imaging and macroscopic validation in mouse colon ex vivo. The results of a pull-down assay supported specific binding of QQT*-Cy5.5 to mouse cMet-ECD, Fig. S4B . A rigid small animal endoscope was used to collect in vivo images in CPC;Apc mice. A representative flat lesion displayed bright fluorescence after intra-rectal administration of QQT*-Cy5.5, while minimal signal was seen when the same lesions were imaged 3 days later using TLQ*-Cy5.5, Fig. 5A -D, Videos S1-S3. Similar results were obtained from a representative polypoid lesion, Fig. 5E -H, Videos S4-S6. A ratio of fluorescence and reflectance images from the flat lesion was determined to correct for differences in distance and geometry over the image field-of-view (FOV) to allow for image intensities to be accurately quantified, Fig. 5I . Fluorescence, reflectance, and ratio values from the dashed line in Fig. 5I were shown, Fig. 5J . Images collected from polyps were processed similarly. The mean T/B ratio was significantly greater for QQT*-Cy5.5 versus TLQ*-Cy5.5 for flat lesions and polyps, Fig. 5K . Imaging was also performed ex vivo to validate specific binding by QQT*-Cy5.5 to cMet. The colon was excised and divided longitudinally to expose the mucosal surface. White (WL) and fluorescence (FL) images were shown, Fig. 5L ,M. Co-localization at the polyps was seen on the merged image, Fig. 5N . The adenoma borders were clearly seen. The mean fluorescence intensity was significantly greater for polyps versus adjacent normal colonic mucosa, Fig. 5O . 
Validation of cMet expression in human colon.
Staining of human colon with QQT*-Cy5.5 and anti-cMet-AF488 was evaluated in n = 42 formalin-fixed, paraffin-embedded (FFPE) specimens, including tubular adenoma, sessile serrated adenoma (SSA), hyperplastic polyp (HP), and normal mucosa. Merged fluorescence images showed strong co-localization of peptide and antibody binding for each histological classification, Fig. 6A -D. Immunofluorescence of SSA specimens showed large, dilated crypts with numerous goblet cells to suggest abnormal maturation. Immunohistochemistry was performed to validate cMet expression. Strong staining (2+/3+) was observed for adenoma and SSA while weak staining (0+/1+) was seen for HP and normal, Fig. 6E -H. Representative histology (H&E) was shown, Fig. 6I -L. The mean fluorescence intensity from staining with QQT*-Cy5.5 was significantly greater for either adenoma or SSA versus either HP or normal colon, Fig. 6M . A total of n = 11 SSA lesions were described endoscopically with a flat appearance, and n = 2 were documented to be slightly protruding from colonoscopy reports. www.nature.com/scientificreports www.nature.com/scientificreports/
Discussion
Here, a linear, 7mer peptide specific for cMet was identified using methods of phage display by biopanning against the extracellular domain (ECD) of the purified protein. The peptide was labeled with Cy5.5, a NIR fluorophore, to demonstrate proof-of-concept for in vivo imaging as a targeted contrast agent. Specific binding was validated in vitro using human CRC cells with knockdown, competition, and co-localization studies. A binding affinity of k d = 57 nM and binding onset of k = 0.62 min −1 (1.6 min) were measured. Unlike HGF, peptide binding shows no effect on downstream cell signaling. Fluorescence images collected in vivo from flat and grossly visible polyps in the colon of CPC;Apc mice showed high T/B ratios. Fluorescence images collected ex vivo from human colon specimens supports strong peptide binding to traditional adenomas and SSAs. Significantly less signal was seen with hyperplastic and normal colon. Experiments were controlled with a scrambled peptide. Current endoscopic methods for early detection of CRC use white light illumination alone, and are not sensitive to flat lesions. Molecular targets are expressed well before structural changes become apparent, such as polyp formation. Peptides developed for overexpressed targets can be used to detect pre-malignant lesions that are flat in appearance and easily missed during colonoscopy with white light illumination alone. The fluorescence images collected in vivo from flat pre-malignant lesions in mouse colon illustrate this approach. In our study, n = 7 lesions with non-polypoid morphology were visible only on fluorescence images generated following peptide binding. All of these flat lesions were identified as dysplasia on pathology. The CPC;Apc mice used for imaging were genetically engineered to somatically delete an APC allele under Cre regulation, and adenomas develop spontaneously in the distal colon 39 . This model is representative of human disease as Apc mutations are found in > 80% of sporadic colorectal cancers 40 . Most SSAs and many sporadic adenomas have a flat appearance during colonoscopy. The serrated and traditional signaling pathways account for >95% of all sporadic CRC's 41, 42 . The remaining ~5% is attributed to genetic syndromes, such as hereditary nonpolyposis colorectal cancer (HNPCC) and familial adenomatous polyposis (FAP) 43, 44 .
A 26-mer cyclic peptide specific for cMet has been previously developed. This peptide was labeled with a modified Cy5 fluorophore, and was used to collect clinical images with a fluorescence colonoscope 21 . This peptide was found to have high affinity with a k d = 3 nM. Imaging was performed ~3 hours post-injection to allow time for background to clear. A total of n = 15 patients at high risk for CRC were studied, and n = 101 tubular adenomas were detected with white light illumination alone. An additional n = 22 adenomas were found with fluorescence. The mean T/B ratio was only slightly greater than 1. Our peptide is much smaller in size (7 versus 22 amino acids), and provides less surface area for non-specific interactions that can increase background. Although the binding affinity is not as strong (57 versus 3 nM), it appears to be adequate for in vivo use as a diagnostic imaging agent. Immunofluorescence of human sections was performed to support specific binding by this peptide.
Phage display was used previously to identify a different 12-mer peptide by subtractive biopanning against whole S114 cells genetically engineered to overexpress cMet. This peptide was radiolabeled with 125 I, and nuclear images were collected from mouse xenograft tumors in vivo. Cancer-associated activity was seen up to 24 hours post-injection 45 . A binding affinity of k d = 64 nM was measured using cells in vitro. This result is comparable with ours. No staining of human tissues was performed to assess for clinical relevance, and the experiments performed were not controlled using an alternate sequence. By comparison, we biopanned a phage display library against purified cMet-ECD protein. This approach minimizes non-specific interactions with non-target proteins expressed on the cell membrane, and should improve binding specificity.
Large molecules, such as antibodies, that have high target affinity are also being utilized for CRC imaging. Bevacizumab is a monoclonal antibody that has been repurposed for imaging by labeling with IRDye800 to detect overexpressed vascular endothelial growth factor A (VEGFA) 46 . This imaging agent was intravenously administered in a total of n = 17 patients with familial adenomatous polyposis (FAP), and n = 51 adenomas were detected. A median T/B ratio = 1.84 was achieved using a dose of 25 mg. Small adenomas with dimensions< 3 mm were detected. Antibodies have long circulation times that lead to increased background. Peptides, by comparison, are much smaller in size and lower in molecular weight. These properties can be developed to overcome many challenges for probe delivery, including irregular microvasculature, heterogeneous uptake, and transport barriers [47] [48] [49] . Improved diffusion and extravasation through leaky vessels can result in higher concentrations and deeper penetration [50] [51] [52] . Also, peptides have less potential for immunogenicity 53 .
This study demonstrates promise for a small fluorescently-labeled peptide to detect pre-malignant colonic lesions in vivo. The reduced size may decrease background, immunogenicity, and cost for mass manufacture. These features can overcome some of the limitations of larger ligands, and are well suited for clinical use in high volume procedures, such as colonoscopy. In this study, the peptides were administered intra-rectally in a mouse model of CRC for convenience. Intravenous administration is needed for adequate distribution throughout all colonic segments. The pharmacokinetics and stability of this peptide in circulation should be characterized. Use of IRDye800 to label the peptide may improve tissue penetration depth and water solubility. Immunofluorescence results using human colon specimens support peptide binding to sporadic adenomas and SSAs. This approach has potential to detect missed pre-malignant lesions that arise from the traditional and serrated signaling pathways. cells lines, culture media and chemicals. Human HT29, SW480, CCD841 colorectal cancer cells and mouse NIH 3T3 embryonic fibroblast cells were obtained from the ATCC. S114 cells (NIH 3T3 cells transformed to express cMet) were provided by courtesy of G Vande Woude (Van Andel Institute). McCoy's 5A Medium (Gibco) was used for HT29 cells. Dulbecco's Modified Eagle Medium (Gibco) were used for SW480, NIH3T3, and S114 cells. Eagle's Minimum Essential Medium (Lonza) was used for CCD841. All cells were cultured at 37 °C in 5% CO 2 , and supplemented with 10% fetal bovine serum. Reagents for peptide synthesis were obtained from Anaspec (Anaspec) and AAPPTEC (AAPPTEC) at the highest available grade (>99% purity), and were used without further purification. Solvents and other chemical reagents were purchased (Sigma-Aldrich) unless stated otherwise. www.nature.com/scientificreports www.nature.com/scientificreports/ (10692-H08H, Sino Biological Inc) for 4 rounds 54 . Candidate phages with the highest enrichment were selected for further evaluation. Reactivity to HT29 cells was assessed using enzyme-linked immunosorbent assay (ELISA). Binding interactions between the candidate peptides and cMet were assessed with non-intact structures 1UX3 and 2UZX using Pepsite software 55 . Peptides were synthesized using standard Fmoc-mediated solid-phase chemistry using an automatic synthesizer (PS3, Protein Technologies Inc) 56 . The C-terminus was labeled with Cy5.5 (Lumiprobe) via a 5 amino acid (GGGSK) linker. Crude peptides were purified with HPLC (Waters) using a C18 column. The final purity was confirmed using an analytical C18 column. The mass-to-charge ratio (m/z) was measured using mass spectrometry (MALDI-TOF, Bruker AutoFlex Speed).
Methods
Spectral measurements. The peptide absorbance spectrum was measured using a UV-Vis spectrophotometer (NanoDrop 2000, Thermo Scientific). Fluorescence emission was collected with a fiber coupled spectrophotometer (Ocean Optics) using a diode pumped solid state laser (Technica Laser Inc) with excitation at λ ex = 671 nm. The spectra were plotted using Origin 6.1 software (OriginLab Corp).
Confocal fluorescence microscopy. The cells were blocked with 1X PBS plus 2% BSA for 1 hour at 4 °C, and were incubated with 5 μM of peptide for 10 min at room temperature (RT) in the dark, washed 3×, and fixed with 4% PFA for 5 min, washed with 1X PBS, and then mounted on glass slides with ProLong Gold reagent containing DAPI (Invitrogen). A 1:3000 dilution of primary monoclonal rabbit anti-cMet antibody (#8198, Cell Signaling Technology) was incubated with the cells in vitro as a positive control. Afterwards, the cells were incubated with a 1:500 dilution of AF488-labeled secondary goat ant-rabbit immunoglobulin G antibody (#A-11029, Life Technologies), and then mounted on glass slides with ProLong Gold reagent containing DAPI. Confocal fluorescence images were collected using a 63X oil-immersion objective (Leica SP5 Inverted 2-Photon FLIM confocal). Fluorescence intensities were quantified using custom Matlab software (Mathworks). The time scale for peptide binding to HT29 cells was assessed by estimating the apparent association time constant k. HT29 cells were incubated with 5 μM of Cy5.5-labeled peptides for time intervals ranging between 0 and 20 min at 4 °C. The cells were fixed with 4% PFA for 30 min at 4 °C before analyzing with flow cytometry. The rate constant was calculated by fitting the data to a first-order kinetics model y(t) = I max [1− exp(−kt)], where I max is the maximum value, using Prism 5.0 software (GraphPad) 58 .
Downregulation of cMet with siRnA. Expression of cMet by HT29 cells was knocked
Interactions between peptide and mouse cMet were evaluated using a pull-down assay 59 . Peptides were immobilized on EHS active beads (17-0906-01, GE), and incubated with purified mouse cMet-ECD protein (50622-M08H, Sino Biological). After washing, bound proteins were detected by Western blot.
Effect of peptide on cell signaling. HT29 cells were treated with serum free medium overnight for starvation before incubation with either HGF or peptides. HGF was added at concentrations of 25 ng/mL for 10, 30, and 120 min in separate wells. Peptides are added at concentrations of 5 and 100 μM for 10, 30, and 120 min. Anti-cMet antibody (#8198, Cell Signaling), phospho-cMet (Tyr1234/1235) antibody (#3077, Cell Signaling), anti-AKT (#4691, Cell Signaling), anti-phospho-AKT (#9271, Cell Signaling), anti-ERK1/2 (#ab17942, Abcam,), anti-phospho-ERK1/2 (#ab50011, Abcam), and anti-tubulin (#32-2600, Invitrogen) were used per manufacturer's instructions.
An alamar blue assay was performed using HT29 and CCD841 cells. After culturing in serum free media overnight, ~3 × 10 3 cells were seeded per well in serum free media in 96 well plates at a final volume of 100 µL per well. The cells were incubated with either HGF (25 ng/mL) or peptide (5 and 10 μM) at 37 °C for 48 hours. Alamar blue reagent (10 µL) was added in amounts equal to 10% of the volume in the well, and incubated at 37 °C for 4 hours. Fluorescence with excitation at λ ex = 530-560 nm, and emission at λ ex = 590 nm was measured.
In vivo imaging and macroscopic validation in mouse colon ex vivo. CPC;Apc mice were used for in vivo imaging. This mouse was genetically engineered to sporadically delete an adenomatous polyposis coli (APC) allele under control of a Cdx2 promoter (CDX2P-9.5NLS-Cre) to spontaneously form either flat or polypoid adenomas in the distal colon 39 . Prior to imaging, the mice were fasted for 4-6 hours. Anesthesia was induced and maintained via a nose cone with inhaled isoflurane mixed with oxygen at concentrations of 2-4%
